Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$17.24 USD
+0.56 (3.36%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $18.00 +0.76 (4.41%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Travere Therapeutics, Inc. has a market cap of $1.48B, which represents its share price of $16.68 multiplied by its outstanding shares number of 88.81M. As a small-cap company, TVTX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TVTX 17.24 +0.56(3.36%)
Will TVTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
Other News for TVTX
Travere Therapeutics Non-GAAP EPS of $0.13 beats by $0.14, revenue of $114.45M beats by $14.28M
Travere Therapeutics Inc Reports Q2 2025 Earnings: EPS Loss of $0. ...
Earnings Scheduled For August 6, 2025
Travere Therapeutics reports Q2 EPS (14c), consensus (1c)
Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result